CapsoVision (CV) Q3 2026 earnings review
CapsoVision clears its AI software, but capsule sales stall
CapsoVision, a maker of swallowable camera capsules that film the gut, hit its regulatory targets while its existing sales stalled. Third-quarter revenue barely budged at $3.6 million, and gross margin fell 5 percentage points because of higher memory chip costs and an inventory write-off. Chief executive Johnny Wang launched the company's FDA-cleared artificial intelligence reading software in the US in November and raised $19.5 million by selling new shares.
| Revenue | $3.57M +0.8% from a year ago |
|---|---|
| Gross margin | 49% 54% a year ago |
| Cash and equivalents | $21.8M after $19.5M net stock sales |
| Colon FDA filing outlook | Unchanged on track for year-end 2026 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because clearing the regulatory hurdles and refilling the bank account balanced out flat sales and heavy share dilution. Completing the colon capsule clinical trial already lowered research spending and kept the year-end FDA filing on track. One caution: the company grew its share count by 7% in a single quarter by our math to fund operations, and pushed the full sales benefit of its new software into 2027.
The question now is whether the new AI reading software brings in new clinic buyers or only keeps current customers from cutting prices. If it wins new clinics, capsule sales will speed up; if it only defends prices, revenue growth will stay slow. Fourth-quarter and early 2027 sales figures will tell.
🐂 Bull Case
FDA Cleared the New AI Reading Tool
CapsoVision makes CapsoCam Plus, a swallowable camera capsule that films the small intestine. Chief executive Johnny Wang said that "The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision".
Regulators cleared AI Highlights, software that uses artificial intelligence to help doctors review capsule videos, on September 25. The medical device maker launched the tool in the US on November 2 for patients aged two and older.
This launch matters because rival capsules already had cleared AI tools, which forced the company to cut its prices by 3% last quarter. Average selling prices held steady from a year ago in the third quarter, and management expects the software "to accelerate CapsoCam Plus sales growth, with the full commercial impact anticipated in 2027".
What to watch: fourth-quarter revenue and capsule volume in the annual report. Those figures will show the first two months of US commercial sales and whether the software brings in new clinic accounts.
Colon Capsule Trial Finished Enrolling Patients
CapsoVision is developing a second-generation capsule, CapsoCam Colon, to screen the large intestine for polyps without a traditional colonoscopy. Wang said that "completing enrollment in our colon clinical study brings us closer to our planned FDA submission by year end, which we believe represents a substantially larger market opportunity".
The company finished enrolling patients and collecting clinical data, including doctor reviews of videos with and without AI assistance. Winding down the trial allowed management to cut research and development spending, which is the cost of running clinical studies and engineering new products.
- Research and development expense: $4.8 million, down 21% from a year ago
- Research and development share of revenue: 134.6%, down 37.5 percentage points from a year ago by our math
- Operating loss: $7.4 million, narrowed from $8.0 million a year ago
What to watch: confirmation of the FDA application filing by the end of December 2026. Filing on time would keep the colon capsule on track for a potential regulatory decision in 2027.
🐻 Bear Case
Share Sales Funded the Cash Burn
CapsoVision spends far more cash on clinical trials and overhead than it collects from selling camera capsules. Because operations lose money every quarter, the diagnostics group relies on issuing new stock to stay in business.
In September, the California company raised $17.8 million in net proceeds by selling stock directly to existing shareholders, and raised another $1.7 million through its at-the-market share sale program. Those two financings lifted cash on hand to $21.8 million, up from $9.1 million in June.
- Common shares issued and outstanding: 53.6 million, up 7.1% in a single quarter by our math
- Operating cash burn in the third quarter: $7.0 million by our math
- Nine-month stock-based compensation: $1.9 million, triple the $0.6 million recorded a year ago
The cash injection gives the business roughly three quarters of breathing room at its third-quarter burn rate. However, selling stock so often shrinks each existing shareholder's slice of future products before the colon capsule even reaches regulators.
What to watch: fourth-quarter operating cash burn and additional at-the-market share sales in the annual filing. If cash burn stays near $7 million a quarter, management will need to tap the equity program again in 2027.
Component Costs and Write-offs Cut the Margin
In the first half of 2026, management blamed US tariffs and competitor pricing for falling profitability, while building up inventory to meet demand. This quarter, the cost of making the capsules rose 4.7 percentage points of revenue from a year ago, pushing gross margin down 5 percentage points to 49%.
CapsoVision said the drop reflected "higher material costs associated with increased flash memory prices, a one-time inventory obsolescence charge, and higher stock-based compensation expense". Taking an obsolescence write-off cuts against the earlier claim that the 59% year-to-date inventory buildup to $4.75 million was purely for rising customer demand.
What to watch: the exact dollar size of the inventory write-off in the third-quarter filing notes. A large write-off would show that older capsule components went unused while the company waited for FDA clearance.
Revenue Growth Slowed to Near Zero
CapsoVision currently earns all of its revenue from CapsoCam Plus capsules and related reading software. Total sales in the third quarter came in at $3.57 million, up 0.8% from $3.54 million a year ago and down 2.1% from the second quarter by our math.
The company reported that over 184,000 patients have used the capsule, an increase of 8,000 patients from June and up 22% from a year earlier. Selling and marketing expenses — the cost of the sales force and clinic outreach — rose 7.6 percentage points of revenue from a year ago to $2.06 million, but top-line sales barely moved.
What to watch: fourth-quarter revenue compared with last year's $3.90 million fourth-quarter total. Because US sales of AI Highlights only started in November, weak fourth-quarter growth would show that clinics are slow to order before 2027.
Risks this quarter didn't answer
Four standing concerns from prior filings received no numerical update in the third-quarter press release.
- Pancreatic cancer trial patient count: the company signed a third clinic and is talking to "more than a dozen larger medical centers with expertise in pancreatic ductal adenocarcinoma (PDAC)", but gave no patient count after having only three enrolled in June.
- Customer concentration: one buyer previously accounted for 11% of revenue and 25% of unpaid bills; the quarterly filing will show if that reliance grew.
- Asian supply-chain exposure: reliance on component suppliers in Taiwan and Japan remains an unquantified risk in the release.
- Capsule delivery device launch: management previously planned full commercialization in the fourth quarter of 2026, and the release did not mention the device.
💲 Other KPIs
Unpaid customer bills rose 31.3% from a year ago and 8.4% from last quarter, outpacing the 0.8% rise in revenue. Accounts receivable is money clinics owe for capsules already shipped, and its rise tied up cash during the quarter.
Deferred revenue — cash customers have paid upfront for CapsoCloud software reading services not yet delivered — grew 37.7% from a year ago and 4.3% from June. The yearly growth rate slowed from 44.3% in the second quarter, and the balance equals 4% of quarterly sales.
🔮 Guidance
Unchanged. Management still plans to submit its second-generation colon capsule application to the FDA by the end of 2026. The company finished patient enrollment and video reviews this quarter, after having pushed the target back from the third quarter earlier this year.
Unchanged. The endoscope maker expects the November US launch of AI Highlights to speed up capsule sales growth, with the main benefit arriving in 2027. By our math, its earlier plan for second-half sales to exceed first-half sales of $6.44 million requires at least $2.87 million in the fourth quarter, which is 26% below last year's fourth quarter.
New. The company expects clinical trial expenses to fall now that patient enrollment and data collection in the pivotal colon study have ended. Research and development spending already dropped 9.5% from the second quarter to $4.80 million.
❓ Key Questions
How is AI Highlights priced for US clinics?
Management expects the new AI software to speed up sales growth in 2027, and average selling prices stabilized this quarter. Did the company charge a separate software fee for the November launch, or bundle it for free to defend capsule prices?
How large was the third-quarter inventory write-off?
Gross margin fell 5 percentage points to 49% partly due to an inventory obsolescence charge, even as total inventory sits 59% above December levels at $4.75 million. Investors need the dollar amount of the write-off and what caused the parts to spoil.
How many patients are enrolled in the pancreatic trial?
CapsoVision signed a third clinic site and is talking to over a dozen medical centers for its upper gastrointestinal pancreatic study. Because only three patients were enrolled as of June, how many of the planned 140 patients have joined so far?
What happened to the fourth-quarter capsule delivery device launch?
Last quarter's filing stated that full commercialization of the capsule delivery device was expected in the fourth quarter of 2026. The third-quarter release did not mention the device, leaving open whether that launch is still on schedule.